Clinical Trials Logo

Filter by:
NCT ID: NCT04948840 Recruiting - Breast Cancer Clinical Trials

Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis

TREM-1
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Breast cancer is the most common cancer in the world. Half of patients with such cancer are treated with radiation therapy. Some patients will develop cutaneous or subcutaneous fibrosis, more or less bothersome. Several studies have shown a correlation between an inflammatory reaction and a protein, called TREM-1. But to date, no link has been proven between TREM-1 and inflammation / fibrosis in the phenomena of fibrosis induced by radiotherapy in patients with breast cancer. Our study aims to understand the involvement of this TREM-1 protein in the development of fibrosis or radio-epidermis in patients with breast cancer.

NCT ID: NCT04971096 Recruiting - Clinical trials for Mild Cognitive Impairment (MCI)

Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

This study is to evaluate whether the consumption of probiotics can improve the symptoms of patients with mild cognitive impairment; also evaluate the effects of probiotics on patients' blood, oxidation and stress related indicators.

NCT ID: NCT04976231 Recruiting - Clinical trials for Mucopolysaccharidosis II

MPS II Immunophenotyping

Start date: April 1, 2022
Phase:
Study type: Observational

The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.

NCT ID: NCT04981223 Recruiting - Prostate Cancer Clinical Trials

Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to use a clinical micro-ultrasound to systematically image the prostate before biopsy or surgery. The images from the ultrasound system will be saved and compared to other imaging modalities and pathology in order to develop better tools.

NCT ID: NCT04983030 Recruiting - HIV Clinical Trials

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Start date: April 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an Ad26.Mos4.HIV prime and a boost with Modified Vaccinia Ankara (MVA)-BN-HIV in combination with broadly neutralizing antibodies (bNAb) PGT121, PGDM1400, and VRC07-523LS in human immunodeficiency virus type 1 (HIV-1)-infected study participants on suppressive anti-retroviral therapy (ART).

NCT ID: NCT04994197 Recruiting - Clinical trials for Urothelial Carcinoma

Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS

Start date: April 1, 2022
Phase:
Study type: Observational

Genetron Uro V1 perform mutation detection of 17 genes and methylation detection of 1 gene by using urine samples and tumor tissue samples. It is a urine liquid biopsy method that has a great supplementary effect on the existing clinical differential diagnosis technology. The main aim of this study is to compare the test results of Genetron Uro V1 with the standard clinical diagnosis results, and analyze the performance of Genetron Uro V1 in the diagnosis and recurrence diagnosis of urothelial carcinoma.

NCT ID: NCT05008848 Recruiting - Clinical trials for Cigarette Smoking-Related Carcinoma

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Start date: April 1, 2022
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.

NCT ID: NCT05025826 Recruiting - Clinical trials for Metastatic Gastric Cancer

Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy

PROPERTY
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. The phycocyanin (PC), a biliprotein pigment and an important constituent of the blue-green alga Spirulina platensis, has been reported to possess significant antioxidant and radical-scavenging properties, offering protection against oxidative stress. Study hypothesis is that phycocyanin may give protection against oxaliplatin-induced neuropathy in the treatment of gastro intestinal cancers including oesogastric, colo-rectal and pancreatic cancers. This trial will be a randomised placebo-controlled study.

NCT ID: NCT05030441 Recruiting - Clinical trials for Clonal Cytopenia of Undetermined Significance

Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients. The study will also be offered in a decentralized, remote structure to patients.

NCT ID: NCT05051644 Recruiting - Chronic Pain Clinical Trials

An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment

Start date: April 1, 2022
Phase: Phase 1
Study type: Interventional

Severe chronic pain and opioid use disorder (OUD) occur at significantly higher rates in Veterans compared to the general population. Chronic pain often persists despite engagement in opioid agonist treatment (OAT), the first line treatment for OUD. Recent VA guidelines strongly recommend non-pharmacologic treatment for chronic pain, but individuals with OUD are frequently excluded from pain treatment studies. There is a need for evidence-based pain treatments that compliment OAT for Veterans with chronic pain and OUD. In this study, the investigators will determine feasibility and acceptability for a behaviorally focused pain treatment that includes pain education and a pedometer assisted adaptive walking program for Veterans receiving OAT for OUD. Potential treatment outcomes will be repeatedly assessed using a mobile device, and study-provided pedometers. By offering pain treatment within OAT clinical care, the investigators hope to decrease stigma and increase access for Veterans with chronic pain and OUD.